Amplification of the Plasmodium falciparum multidrug resistance 1 gene (pfmdr1) has been implicated in multidrug resistance, including in vitro resistance to artelinic acid (AL). The stability and fitness of having multiple copies of pfmdr1 are important factors due to their potential effects on the resistance phenotype of parasites. These factors were investigated by using an AL-resistant line of P. falciparum (W2AL80) and clones originating from W2AL80. A rapid reduction in pfmdr1 copy number (CN) was observed in the uncloned W2AL80 line; 63% of this population reverted to a CN of <3 without exposure to the drug. Deamplification of the pfmdr1 amplicon was then determined in three clones, each initially containing three copies of pfmdr1. Interestingly, two outcomes were observed during 3 months without drug pressure. In one clone, parasites with fewer than 3 copies of pfmdr1 emerged rapidly. In two other clones, the reversion was significantly delayed. In all subclones, the reduction in pfmdr1 CN involved the deamplification of the entire amplicon (19 genes). Importantly, deamplification of the pfmdr1 amplicon resulted in partial reversal of resistance to AL and increased susceptibility to mefloquine. These results demonstrate that multiple copies of the pfmdr1-containing amplicon in AL-resistant parasites are unstable when drug pressure is withdrawn and have practical implications for the maintenance and spread of parasites resistant to artemisinin derivatives.
The development and spread of drug resistance in Plasmodium falciparum has become a major public health obstacle, making case management and control of malaria increasingly difficult. To date, P. falciparum parasites have developed resistance to almost all antimalarial agents, including conventional drugs such as chloroquine and sulfadoxine-pyrimethamine and newer drugs such as atovaquine and mefloquine (MFQ) (20) .
Artemisinin (ART) and its derivatives are currently the most effective drugs available to treat multiple-drug-resistant P. falciparum. ART-based combination therapies are now recommended by WHO as first-line treatment of uncomplicated falciparum malaria in areas where the disease is endemic (20) . However, there is a growing concern that the parasites are also developing resistance to ART. This concern has been reinforced by recent reports of delayed parasite clearance and an increase in treatment failures following artesunate monotherapy in western Cambodia (9, 14) . Clearly, parasites in some areas are becoming less susceptible to artesunate, but the molecular mechanism remains unknown.
Resistance to ART derivatives has been successfully induced in vitro by subjecting parasites to increasing concentrations of artelinic acid (AL) (6) . The resulting AL-resistant parasites were also resistant to ART. Resistant parasites from three parasite lines were developed and characterized for molecular changes correlating with the resistance phenotype. In two of the three AL-resistant progeny, amplification of pfmdr1 and increased mRNA transcription and protein expression were detected, while no changes in the coding sequences of several implicated genes, including pfmdr1, pfcrt, pfatp6, pftctp, and pfubcth, or in the expression of pfatp6 and pftctp were observed (6) . The amplification involved a fragment of chromosome 5 up to ϳ100 kb in size which contained many genes, including pfmdr1. The study demonstrated that P. falciparum parasites are capable of developing resistance against ART derivatives in vitro and that pfmdr1 amplification is one of the mechanisms involved in the development of resistance to AL. It also raised several important questions as to whether the amplicons containing pfmdr1 are stable and, if not, whether deamplification of the amplicon restores susceptibility to AL. This has practical implications for the stability of resistance to ART in the field and may provide useful information about potential containment strategies.
pfmdr1 amplification was observed in parasites resistant to MFQ in vitro (7, 21) and in field isolates with reduced susceptibility to MFQ collected from Southeast Asia (4, 5, 22) . It has also been associated with artesunate-MFQ combination treatment failure (17) , demonstrating the important role pfmdr1 plays in parasite resistance against MFQ. Multiple copies of pfmdr1 result from amplifications of a section of chromosome 5 which contains the gene. The amplicons reported vary in size from 14.7 to 50 kb, contain between 2 and 11 genes, and are arranged in tandem with various breakpoints in parasites of different geographical origins (reviewed in reference 2). Multiple copies of the amplicon may also affect the transcription of genes remote to the region, as suggested by the results of a recent study (10) .
While it is clear that pfmdr1 amplification occurs frequently in vitro and in vivo, the stability and fitness of the parasites with an amplification of this large chromosomal segment have not been fully addressed. A reduction in pfmdr1 copy number (CN) was observed in a clone of FCB8 when the parasite was under stepwise selection with chloroquine, a process which resulted in higher susceptibility to MFQ (3). More recently, the stability of the amplified pfmdr1 following MFQ selection in vitro was investigated, with the pfmdr1 CN being maintained after cultivation in an MFQ-free medium for up to 6 months (16). However, the parasites appeared to be less fit than those with a single copy of pfmdr1. Since the study measured the average copy number in an uncloned population possibly containing mixed genotypes, it was impossible to assess whether any subpopulations had undergone deamplification or the dynamics of any deamplification.
The availability of AL-resistant parasites provides a unique opportunity to study the stability of the resistant phenotype and its underlying molecular mechanism, the relationship between drug susceptibility and the number of amplicons, and the fitness of parasites with different numbers of amplicons. In the current study, we addressed these questions by using clonal parasite populations originating from an AL-resistant line, W2AL80. We present evidence that deamplification of pfmdr1-containing amplicons occurs rapidly once drug pressure is withdrawn and define the dynamics of the deamplification and its relationship with drug susceptibility.
MATERIALS AND METHODS
Cultivation and cloning of P. falciparum parasites. Artelinic acid-sensitive (3D7 and W2) and -resistant (W2AL80) P. falciparum parasites described previously (6) were cultivated in vitro as described by Trager and Jensen (19) . To investigate the stability of pfmdr1 CN, the W2AL80 (uncloned) parasites were cultured for 4 months with (W2AL80 ϩ line) or without (W2AL80 Ϫ line) AL pressure. AL at 80 ng/ml was added to the W2AL80 ϩ culture at the start of the 4 months and was temporarily withdrawn from the culture every time parasite growth was completely halted. AL was reintroduced when the parasites were recovered morphologically and resumed normal growth. Following the 4 months of cultivation, both the W2AL80 ϩ and W2AL80 Ϫ cultures were maintained for a further 3 months without drug pressure. At the end of the first 4-month period, the W2AL80 ϩ and W2AL80 Ϫ cultures were cloned by limiting dilution at a calculated density of 0.3 parasites per well. All parasite clones were analyzed by real-time quantitative PCR to determine the CN of pfmdr1 as previously described (6) . Three clones originating from W2AL80 ϩ which were determined to have 3 copies of pfmdr1 (clones 3A, 3B, and 3C) were cultured for 3 months without drug pressure and subsequently recloned as described above. The experimental procedures are summarized in Fig. 1 . Growth competition. Growth competition between parasite clones with 3 copies of pfmdr1 (3A and 3B) and those with a single copy (1A and 1B) was studied using a previously described method (15) . Briefly, the clones were synchronized at ring stage with 5% D-sorbitol (12) for 2 consecutive cycles. Clones 3A and 1A and 3B and 1B were mixed at a 1:1 ratio and continuously cultured for 3 months without drug pressure. Samples of the cultures were taken before and after the 3-month period for analysis of the amplicons on chromosome 5 using pulsed-field gel electrophoresis (PFGE) as previously described (6) .
Genomic DNA extraction. Genomic DNA was extracted from cultured parasites using a QIAamp DNA mini kit (Qiagen) following the manufacturer's instructions. pfmdr1 copy number (CN) determination using real-time quantitative PCR. The pfmdr1 CN was determined using a real-time quantitative PCR as previously described (6) . For purposes of categorizing the results, copy numbers of 2.5 to 3.5, 1.5 to 2.4, and Ͻ1.5 were described as CN 3, 2, and 1, respectively.
Determination of pfmdr1 amplicon. The copy numbers of 6 genes located upor downstream of pfmdr1 were determined by real-time PCR. These genes and their locations on chromosome 5 in relation to pfmdr1 are PFE1090w (Ϫ69,656 kb), PFE1095w (Ϫ63,161 kb), PFE1120w (Ϫ21,575 kb), PFE1160w (ϩ3,974 kb), PFE1180c (ϩ22,940 kb), and PFE1185w (ϩ27,856 kb). Primer sequences and PCR conditions are listed in Table 1 .
In vitro drug susceptibility test. The susceptibilities of parasite lines and clones to AL (molecular weight, 418.48) and MFQ (molecular weight, 378.312) were evaluated by determining the inhibition of [ 3 H]hypoxanthine uptake as described by Desjardins et al. (8) . The concentrations which inhibit 50% and 90% of parasite growth (IC 50 and IC 90 ) were calculated using nonlinear regression analysis of the inhibition of uptake and log-transformed concentrations using GraphPad Prism (version 5). All tests were done in triplicate.
PFGE and Southern blot hybridization. Agarose blocks containing parasite chromosomal DNA were digested with SmaI and analyzed by PFGE followed by Southern blot hybridization as previously described (6) .
Data analysis. Mean copy numbers were compared between groups using either an unpaired t test or a one-way analysis of variance with post hoc test.
RESULTS
Selection and maintenance of AL-resistant P. falciparum W2AL80 in vitro with and without AL pressure. The W2AL80 ϩ line was cultured in vitro under on-and-off AL (80 ng/ml) pressure for 4 months, and the W2AL80 ϩ parasites were able to survive for more than 20 days of continuous drug pressure. The W2AL80 Ϫ line was cultured without AL for 4 months concurrently.
pfmdr1 CN remains unchanged under AL pressure but decreases when AL pressure is withdrawn. The W2AL80 line has 3 copies of pfmdr1 (6) . To determine whether any changes in pfmdr1 CN occurred in this parasite line following cultivation for 4 months with and without AL pressure, both the W2AL80 ϩ and W2AL80 Ϫ lines were cloned at the end of the 4th month of culture. Thirty and 32 clones from the W2AL80 ϩ and W2AL80
Ϫ lines, respectively, were analyzed by real-time quantitative PCR. Twenty-eight of the 30 clones (93%) from the W2AL80 ϩ line had pfmdr1 CNs between 2.5 and 3.5 (average CN, 2.95), indicating that the AL-resistant parasite retained the amplified pfmdr1 copies under the drug selection pressure. In contrast, only 12 of the 32 clones from the W2AL80 Ϫ line had a pfmdr1 CN of Ͼ2.5 (average CN, 2.08). The difference in mean copy number between the two groups of parasites is highly significant (P Ͻ 0.001), indicating that in the absence of drug, a proportion of the AL-resistant parasites had converted from having 3 copies of pfmdr1 to 2 or 1 copy of pfmdr1 (Fig. 2) .
To confirm this observation, both the W2AL80 ϩ and W2AL80
Ϫ uncloned lines were maintained in culture for a further 3 months without drug pressure. Chromosomal DNA collected from parasite samples before and after the 3-month period were cleaved with SmaI and analyzed by PFGE and Southern blotting. Since SmaI cuts outside the amplicon, producing a band corresponding to the chromosome segment which contains all amplicons (6), the ratio of different SmaI fragments reflects the proportion of the parasites with 3, 2, or 1 copy of pfmdr1. The ratio of CN 3 to CN 2 in both the W2AL80 ϩ and W2AL80 Ϫ lines decreased after the 3-month culture without AL (Fig. 3A) , demonstrating that the 3-copy status of pfmdr1 in W2AL80-resistant parasites was not stable in the absence of AL.
Reduction in pfmdr1 CN and dynamics. To better understand the process of the pfmdr1 CN reduction in W2AL80 parasites without drug pressure, three clones originating from W2AL80 ϩ that each contained 3 copies of pfmdr1 (clones 3A, 3B, and 3C) were cultured without drug for 3 months. Chromosomal DNA of these clones collected before and after the 3-month period was cleaved with SmaI, separated by PFGE, and analyzed by Southern blot hybridization (Fig. 3B) . In clones 3A and 3B, a band at CN 2 was visible by the time the clones had reached a parasitemia high enough to be cryopre-served (23 to 25 days after cloning; "time zero"). The intensity of the CN 2 band in clones 3A and 3B increased after 3 months of cultivation, and a band of CN 1 also appeared in clone 3A (Fig. 3B) . Clone 3C appeared to maintain a CN of 3 at the end of the 3-month culture.
Clones 3A, 3B, and 3C were recloned after the 3-month culture, producing 30, 24, and 30 subclones, respectively. pfmdr1 CN analysis of the subclones generally reflected the results obtained from the Southern blot hybridization (Fig. 4) . Eighty percent (25/30) of subclones from clone 3A had a CN of Ͻ2.5, with the majority of clones having a CN of 1. In the subclones of clones 3B and 3C, only 37.5% (9/24) and 13% (4/30) had a CN of 2, while none had a CN of 1. The mean CN of clone 3A (1.4) was significantly lower than the means for clones 3B (2.6) and 3C (2.9) (P Ͻ 0.001). These results demonstrate that deamplification of the pfmdr1 amplicon occurred in all 3 clones examined, with a higher rate of deamplification in clone 3A than in clones 3B and 3C.
Loss of fitness associated with 3 copies of pfmdr1. To investigate whether there is a fitness cost associated with a higher pfmdr1 CN, two clones originating from the W2AL80 Ϫ line (clones 1A and 1B) that both had a single copy of pfmdr1 were selected and mixed individually with either clone 3A or 3B at a 1:1 ratio and cultured for 3 months without drug pressure. At the end of the 3 months, chromosomal DNA was analyzed by Southern blot hybridization (Fig. 3C) . In the mixture of 1A and 3A, there was a reduction in the intensity of the band corresponding to CN 3 and a band representing 2 copies appeared. This was likely due to the deamplification of the amplicon from 3 copies to 2 copies observed when clone 3A was cultured in isolation. Taking the deamplification into consideration, the overall ratio of CN 3 to CN 1 did not change markedly in this mixture. In contrast, the ratio of 3B to 1B in the second mixture changed markedly, with the intensity of the 1-copy band becoming stronger than that of the 3-copy band, indicating that clone 3B suffered a growth disadvantage compared to clone 1B. The result suggests that a loss of fitness also contributes to the pfmdr1 CN decrease observed in the W2AL80 parasite population.
Loss of the entire pfmdr1 amplicon in the deamplification process. The boundaries of the pfmdr1 amplicons in 10 and 7 subclones of clones 3A and 3C, respectively, were determined by real-time quantitative PCR. The parasite lines 3D7 (CN 1), W2 (CN 1), and W2AL80 ϩ (CN 3) were used as controls. In all 14 clones where the pfmdr1 CN was Ͼ1, the furthest upstream gene amplified was PFE1095, while the furthest downstream gene amplified was PFE1180 (Fig. 5) . The CNs of genes between PFE1095 and PFE1180 were identical to the CN of pfmdr1, while the CN of PFE1190 and PFE1185 was always 1 (Fig. 5) . Therefore, the amplicon in each clone contained 19 genes from PFE1095 to PFE1180. These results suggest that in the process of deamplification, the parasites lost an entire amplicon unit containing 19 genes.
Drug susceptibility profile associated with the CN of the pfmdr1 amplicon. Multiple subclones with various CNs of the pfmdr1 amplicon were tested at the same time in one assay for in vitro susceptibility to AL and MFQ ( (Fig. 6) . Interestingly, subclones 3A1 and 3A3 that had undergone deamplification and only had a single copy of the amplicon region were more susceptible to AL than those clones with multiple copies of the amplicon but were still more tolerant to AL than the parent line W2 (Table  2 and Fig. 6 ). The same pattern was observed when this experiment was repeated; the mean fold increases in IC 90 values (com- (Table 2 ). These results suggest that the pfmdr1 amplicon plays an important role in AL and MFQ resistance in P. falciparum in vitro but that drug susceptibility is not determined solely by pfmdr1 copy number.
DISCUSSION
The amplification of pfmdr1 correlates with a reduction of parasite susceptibility to several antimalarial drugs, including MFQ, halofantrine, lumefantrine, and AL. The stability of the amplicon is an important factor, as it has implications for the evolution of drug resistance. In this paper, we demonstrate for the first time that in the absence of AL pressure, AL-resistant parasites deamplify the entire pfmdr1-containing amplicon, which is associated with a partial restoration of susceptibility to AL and MFQ. The data demonstrate that the pfmdr1-containing amplicon plays an important but not exclusive role in conferring resistance to AL in vitro.
When AL-resistant parasites (W2AL80) were cultured under AL pressure, we observed no change in pfmdr1 copy number, with most of the clones derived from this culture also having 3 copies of the amplicon. In contrast, when the W2AL80 parasites were cultured without the drug pressure, only approximately one-third of parasites retained 3 copies of the amplicon, with most reverting to 2 copies. This reduction was confirmed again when further subclones were created and a significant proportion had CNs of 2 and 1. The data clearly demonstrate that the high-pfmdr1-CN status is not stable when drug pressure is withdrawn. Our results contradict those pub- lished recently which reported that the pfmdr1 CN in MFQresistant parasite populations remained stable following a 6-month cultivation without drug (16) . There are several differences between the studies which could account for the conflicting results. These include methodological differences (cloned versus bulk culture) and differences in the parasites (W2 versus TM036) and drugs (AL versus MFQ) used to select resistance, which may result in differences in the size, gene content, and stability of the amplicon. There are two major causes of instability of the pfmdr1-containing amplicon in a parasite population, deamplification of the amplicons and a fitness loss associated with a higher number of amplicons. In this study, we investigated both of these mechanisms and found that each contributed to the observed instability. The loss of fitness observed can be attributed to the amplification of a large section on chromosome 5 and changes in the pfmdr1 CN, not additional mutations in pfmdr1, as previously reported (11) , or in several resistance gene candidates, such as pfatp6, since no additional mutations were identified in the resistant progeny (6) . Importantly, our study used cloned parasites, allowing us to distinguish deamplification of pfmdr1 from out-growth by a preexisting subpopulation of parasites with a low CN. We observed a rapid deamplification of the pfmdr1-containing amplicon from a CN of 3 to a CN of Ͻ3 in some clones, while other clones showed much slower deamplification. The successive cloning of parasites and observed changes in these clones suggest that the deamplification appears to be a stepwise process, from CN 3 to CN 2 and then to CN 1.
The processes causing deamplification need further investigation but are probably linked to the plasticity of the parasite genome, which readily amplifies this section of chromosome 5 under drug pressure. The responsiveness of the genome to external factors appears to be a parasite-specific characteristic, with some parasites rapidly returning to the "natural" state after removal of drug pressure, while others take longer to revert. The fragment size, boundaries, and gene composition of the amplicon appear to be identical between different subclones, suggesting that all 19 genes within the amplicon are lost during deamplification. It is highly likely that the deamplification occurred at the same site as amplification, indicating that there are amplification/deamplification hot spots on chromosome 5 surrounding pfmdr1. The amplification hot spots have been mapped to the AT-rich noncoding region in MFQ-resistant parasites (1, 13) and are different in different strains.
Just as the rate of deamplification varies between parasites, the results of our growth competition experiment demonstrated that the fitness of parasites carrying multiple pfmdr1 amplicons also varied. In two independent experiments using different parasite clones, we observed one 3-copy clone which suffered a loss of fitness and one that did not appear to be less fit than a 1-copy clone. The relationship between loss of fitness and propensity for deamplification is unclear, but our data suggest that two types of parasites may exist, (i) those that do not suffer a loss of fitness but have a fast deamplification rate and (ii) those that suffer a loss of fitness and are much slower to revert to a lower-copy-number status. The first type would appear more able to compete in a mixed parasite population with a changing environment, while the second type is less responsive and would presumably suffer in a mixed parasite population unless that population was exposed to high levels of drug pressure. If these results are applicable to field parasites, the first type of parasite may cause transient resistance which could be easily contained by removal of the drug. However, the second type of parasite would represent a more severe threat to treatment efficacy in areas with few mixed infections, since the parasite would maintain its resistance markers long after drug pressure was removed, creating a minority population ready to be selected for when drug pressure resumed. Further studies on this second type of parasite are warranted to determine whether they eventually revert to a lower copy number. We have demonstrated that parasite susceptibility to AL and MFQ correlates with the pfmdr1 amplicon CN by using parasites with the same genetic background. However, the pfmdr1 amplicon was not the sole determinant of AL resistance, since the deamplified parasite subclones 3A1 (CN 1) and 3A3 (CN 1) still showed higher average IC 50 and IC 90 values than those of the W2 parent. It is likely that changes in other loci outside the amplicon have occurred during the development of resistance that are also contributing to an increase in resistance/tolerance to AL.
It should be pointed out that, theoretically, any of the 19 genes included in the amplicon could correlate with AL resistance, as they were all amplified during the adaptation to AL pressure and deamplified when drug pressure was withdrawn. However, pfmdr1 (PFE1150w) is the prime candidate since it is the only gene in which mutations or increased copy numbers have been demonstrated to associate with resistance to antimalarial drugs, and genetic disruption of a copy of pfmdr1 resulted in an increase in susceptibility to MFQ, lumefantrine, halofantrine, quinine, and artemisinin (18) .
The amplification of pfmdr1 is implicated in multiple-drug resistance in P. falciparum and plays a major role in the development of AL resistance in vitro. Mathematical modeling based on in vitro experimental data suggests that the pfmdr1 amplification occurs with a frequency of 1 in 10 8 parasites (16) . This increases the concern that parasites may develop resistance to ART derivatives, as amplification of pfmdr1 has already been selected in many areas and the use of ART derivatives has increased dramatically on a global scale in recent years. A containment plan to limit the spread of ART resistance is urgently needed. Our study results demonstrate that deamplification of the pfmdr1-containing amplicon can occur rapidly when AL pressure is withdrawn and, importantly, the deamplified parasites revert to being susceptible to the drug, although not completely. These results, along with the observed loss of fitness in some parasites, suggest that resistance to artemisinin and derivatives may not be stable in the absence of continuous drug pressure unless field isolates have additional beneficial mutations to adjust for decreased fitness from amplification of the pfmdr1 locus.
